Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Glucose→

Glucose Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
50-99-7
Molecular formula
C6H12O6
Molecular weight
180.16 g/mol
Drug class
Monosaccharide carbohydratemetabolic substrate and intravenous energy/electrolyte vehicle
Mechanism of action
Enters glycolysis and oxidative phosphorylation to produce ATP. Intravenous glucose raises blood glucose and provides substrate for cellular energy metabolism; in hyperinsulinaemic states it counteracts hypoglycaemia.
Indications / reported uses
  • Treatment of hypoglycaemia using oral or intravenous glucose, with concentration and route chosen according to severity and clinical setting
  • Intravenous glucose solutions provide fluid and carbohydrate calories and may be used in perioperative or parenteral nutrition settings; these are formulation-specific uses

Sources: NHS — Low blood sugar (hypoglycaemia) treatment · NLM MeSH — Glucose · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Glucose Environmental Risk Assessment (ERA) (the Glucose ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.